[Federal Register Volume 73, Number 54 (Wednesday, March 19, 2008)]
[Notices]
[Pages 14838-14839]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E8-5523]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application

    Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this 
is notice that on February 15, 2008, Lipomed, Inc., One Broadway, 
Cambridge, Massachusetts 02142, made application by renewal to the Drug 
Enforcement Administration (DEA) for registration as an importer of the 
basic classes of controlled substances listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Cathinone (1235)...........................  I
Methcathinone (1237).......................  I
N-Ethylamphetamine (1475)..................  I
Methaqualone (2565)........................  I
Gamma Hydroxybutyric Acid (2010)...........  I
Lysergic acid diethylamide (7315)..........  I
2,5-Dimethoxy-4-(n)-                         I
 propylthiophenethylamine (7348).
Marihuana (7360)...........................  I
Tetrahydrocannabinols (7370)...............  I
Mescaline (7381)...........................  I
3,4,5-Trimethoxyamphetamine (7390).........  I
4-Bromo-2,5-dimethoxyamphetamine (7391)....  I
4-Bromo-2,5-dimethoxyphenethylamine (7392).  I
4-Methyl-2,5-dimethoxyamphetamine (7395)...  I
2,5-Dimethoxyamphetamine (7396)............  I
2,5-Dimethoxy-4-ethylamphetamine (7399)....  I
3,4-Methylenedioxyamphetamine (7400).......  I
3,4-Methylenedioxy-N-ethylamphetamine        I
 (7404).
3,4-Methylenedioxymethamphetamine (7405)...  I
4-Methoxyamphetamine (7411)................  I
Dimethyltryptamine (7435)..................  I
Psilocybin (7437)..........................  I
Psilocyn (7438)............................  I
Acetyldihydrocodeine (9051)................  I
Dihydromorphine (9145).....................  I
Heroin (9200)..............................  I
Normorphine (9313).........................  I
Pholcodine (9314)..........................  I
Tilidine (9750)............................  I
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Amobarbital (2125).........................  II
Pentobarbital (2270).......................  II
Secobarbital (2315)........................  II
Phencyclidine (7471).......................  II
Cocaine (9041).............................  II
Codeine (9050).............................  II
Dihydrocodeine (9120)......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Benzoylecgonine (9180).....................  II
Ethylmorphine (9190).......................  II
Hydrocodone (9193).........................  II
Levorphanol (9220).........................  II
Meperidine (9230)..........................  II
Methadone (9250)...........................  II
Dextropropoxyphene, bulk (non-dosage forms)  II
 (9273).
Morphine (9300)............................  II
Thebaine (9333)............................  II

[[Page 14839]]

 
Oxymorphone (9652).........................  II
Alfentanil (9737)..........................  II
Fentanyl (9801)............................  II
Sufentanil (9740)..........................  II
------------------------------------------------------------------------

    The company plans to import analytical reference standards for 
distribution to its customers for research purposes.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic classes of controlled 
substances listed in schedule I or II, which fall under the authority 
of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may file 
comments or objections to the issuance of the proposed registration and 
may, at the same time, file a written request for a hearing on such 
application pursuant to 21 CFR 1301.43 and in such form as prescribed 
by 21 CFR 1316.47.
    Any such comments or objections being sent via regular mail should 
be addressed, in quintuplicate, to the Drug Enforcement Administration, 
Office of Diversion Control, Federal Register Representative (ODL), 
Washington, DC 20537, or any being sent via express mail should be sent 
to Drug Enforcement Administration, Office of Diversion Control, 
Federal Register Representative (ODL), 8701 Morrissette Drive, 
Springfield, VA 22152; and must be filed no later than April 18, 2008.
    This procedure is to be conducted simultaneously with and 
independent of the procedures described in 21 CFR 1301.34(b), (c), (d), 
(e) and (f). As noted in a previous notice published in the Federal 
Register on September 23, 1975, (40 FR 43745), all applicants for 
registration to import a basic class of any controlled substances in 
schedule I or II are and will continue to be required to demonstrate to 
the Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration, that the requirements for such registration 
pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), 
(c), (d), (e) and (f) are satisfied.

    Dated: March 10, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E8-5523 Filed 3-18-08; 8:45 am]
BILLING CODE 4410-09-P